H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares. The firm says AXS-07 approval in acute treatment of migraine came on time. It sees multiple near- and medium-term clinical and regulatory catalysts for the shares.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics announces FDA approval of Symbravo
- Axsome Therapeutics price target raised to $155 from $125 at TD Cowen
- Axsome Therapeutics participates in a conference call with William Blair
- Axsome Therapeutics price target raised to $180 from $150 at Truist
- Axsome Therapeutics reports Q4 preliminary Auvelity product sales $92.6M